Geneva, Switzerland, May 4th 2015 – EspeRare today announced that the European Medicines Agency (EMA) has granted an Orphan Drug Designation (ODD) for rimeporide, its lead compound for the treatment of Duchenne muscular dystrophy (DMD). DMD is a rare, life-threatening disease affecting boys early in childhood that causes muscle weakness and muscle loss. It is the most common and serious form of paediatric muscular dystrophies.
Find an actor

Journée de l'Innovation 2017 aux HUG Jeudi 19 octobre19.10.2017

11ème Journée de l’innovation au Centre de l’innovation des HUG. Conférences, concours de pitchs, remise des...

BioAlps Recherche...

Un(e) assistant(e) exécutif(ve) à 75%
Print this page Download this page (PDF) Recommend this page to a friend

Contact us

BioAlps Association
Ch. du Pré-Fleuri 3
CH - 1228 Plan-les Ouates
+41 22 304 40 40
+41 22 304 40 70

Subscribe to our newsletter

Find us on LinkedIn